We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.015 | -0.05% | 32.72 | 32.13 | 33.37 | 32.82 | 32.62 | 32.80 | 25,152 | 21:29:37 |
From May 2019 to May 2024
By Colin Kellaher
Pfizer Inc. (PFE) and Merck KGaA's (MRK.XE) EMD Serono unit on Monday said a phase III study of the immunotherapy Bavencio in bladder cancer met its primary endpoint of overall survival at the planned interim analysis.
The companies said patients with previously untreated locally advanced or metastatic urothelial carcinoma whose disease didn't progress on induction chemotherapy and who were randomized to receive first-line maintenance therapy with Bavencio and best supportive care lived significantly longer than those who received best supportive care only.
The companies said Bavencio is the first immunotherapy to significantly prolong overall survival in locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, in a phase III trial.
Germany's Merck and New York-based Pfizer formed a strategic alliance in 2014 to jointly develop and commercialize Bavencio.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 06, 2020 07:37 ET (12:37 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
